EU/3/19/2144

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2144) was granted by the European Commission to Accelsiors Ltd, Hungary, for poly(N-acetyl, N-arginyl)glucosamine (also known as PAAG15A or SNSP113) for the treatment of cystic fibrosis.

Key facts

Active substance
Poly(N-acetyl, N-arginyl)glucosamine
Disease / condition
Treatment of cystic fibrosis
Date of decision
26/02/2019
Outcome
Positive
Orphan decision number
EU/3/19/2144

Sponsor's contact details

Accelsiors CRO and Consultancy Services Ltd
1147 Budapest Xiv
Miskolci Utca 50
Hungary
Tel. +36 1299 0091
E-mail: info@synspira.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating